Location: Sweden
Employees: 11-50
Total raised: $11.26M
Investors 1
| Date | Name | Website |
| - | Scientia V... | scientiavc... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.03.2026 | - | $10M | - |
| 04.03.2025 | Grant | $1.26M | - |
Mentions in press and media 16
| Date | Title | Description |
| 27.03.2026 | Verigraft's P-TEV: Advancing Personalized Regenerative Therapy for CVI | Verigraft launches pivotal Phase II/III trials for P-TEV, a personalized biological therapy. It targets Chronic Venous Insufficiency (CVI), a widespread vascular disease lacking curative treatment. P-TEV replaces diseased veins, ending life... |
| 25.03.2026 | VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial | Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment Fully biologica... |
| 25.03.2026 | VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial | VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial Wed, Mar 25, 2026 12:06 CET Report this content Pivotal Phase II/III clinical trial underway, aiming at US and European market approval in 2028 A ... |
| 12.03.2026 | Biotech company Verigraft secures major investment | Biotech company Verigraft secures major investment Thu, Mar 12, 2026 11:57 CET Report this content Verigraft, a deeptech company based in Gothenburg, has announced a capital injection of SEK 110 million (approx. EUR 10 million) from an exis... |
| 21.08.2025 | 18 Small Businesses Receive Phase I SBIR Funding from NIST | The U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) has awarded more than $1.8 million to 18 small businesses through the Small Business Innovation Research (SBIR) program. The funding will support resear... |
| 28.05.2025 | The Dawn of Personalized Medicine: VERIGRAFT's Breakthrough in Chronic Venous Insufficiency | In the realm of medical innovation, breakthroughs often emerge like a phoenix from the ashes. One such breakthrough is unfolding in Gothenburg, Sweden, where VERIGRAFT AB is pioneering a new frontier in the treatment of Chronic Venous Insuf... |
| 27.05.2025 | VERIGRAFT Receives Regulatory Green Light: Patient Recruitment Completed in Groundbreaking Clinical Trial for Chronic Venous Insufficiency | VERIGRAFT Receives Regulatory Green Light: Patient Recruitment Completed in Groundbreaking Clinical Trial for Chronic Venous Insufficiency Tue, May 27, 2025 07:30 CET Report this content Gothenburg, Sweden – May 27, 2025. VERIGRAFT AB is pl... |
| 27.05.2025 | VERIGRAFT Achieves Regulatory Milestone in CVI Trial | Petter Björquist, CEO, VERIGRAFT Regulatory green light granted as VERIGRAFT completes recruitment in Phase I/II trial of its personalised vein graft for chronic venous insufficiency. This is a critical moment for VERIGRAFT and for the mill... |
| 04.03.2025 | VERIGRAFT Secures €1.2M Eurostars Grant for 3D Printed Vascular Graft Breakthrough | VERIGRAFT, a Swedish biotechnology company specializing in regenerative medicine, has been awarded a €1.2 million Eurostars grant for the PREPPER (PREcision Printed PERsonalized Tissue Therapies) project. The initiative is a collaboration w... |
| 15.02.2025 | VERIGRAFT: Pioneering the Future of 3D-Printed Arterial Grafts | In the world of biotechnology, innovation is the lifeblood. Swedish company VERIGRAFT is poised to make waves with its recent €1.2 million Eurostars grant. This funding will propel the PREPPER project, which stands for Precision Printed Per... |
Show more